HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M200439-JLR200v1 44/4/800    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matthan, N. R. Articles by Lichtenstein, A. H. Search for Related Content PubMed PubMed Citation Articles by Matthan, N. R. Articles by Lichtenstein, A. H. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 44, 800-806, April 2003
Copyright © 2003 by Lipid Research, Inc.

Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL

Nirupa R. Matthan^1,*, Ann Giovanni^*, Ernst J. Schaefer, B. Greg Brown and Alice H. Lichtenstein^*

^* Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111
Division of Cardiology, University of Washington, Seattle, WA 98195

¹ To whom correspondence should be addressed. e-mail: nirupa.matthan{at}tufts.edu

The HDL Atherosclerosis Treatment Study (HATS) demonstrated a clinical benefit in coronary artery disease patients with low HDL cholesterol (HDL-C) levels treated with simvastatin and niacin (S-N) or S-N plus antioxidants (S-N+A) compared with antioxidants alone or placebo. Angiographically documented stenosis regressed in the S-N group but progressed in all other groups. To assess the mechanism(s) responsible for these observations, surrogate markers of cholesterol absorption and synthesis were measured in a subset of 123 HATS participants at 24 months (on treatment) and at 38 months (off treatment). Treatment with S-N reduced desmosterol and lathosterol levels (cholesterol synthesis indicators) 46% and 36% (P < 0.05), respectively, and elevated campesterol and ß-sitosterol levels (cholesterol absorption indicators) 70% and 59% (P < 0.05), respectively, relative to placebo and antioxidant but not S-N+A. Treatment with antioxidants alone had no significant effect. Combining S-N with antioxidants reduced desmosterol and lathosterol by 37% and 31%, and elevated campesterol and ß-sitosterol levels by 54% and 46%, but differences did not attain significance. Mean change in percent stenosis was positively associated with a percent change in lathosterol (r = 0.26, P < 0.005) and negatively associated with a percent change in ß-sitosterol (r = -0.21, P < 0.01).

These data suggest that changes in stenosis were attributable, in part, to changes in cholesterol metabolism.

Supplementary key words desmosterol • lathosterol • campesterol • ß-sitosterol • cholesterol synthesis • cholesterol absorption • statins • niacin • coronary artery disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. R. Matthan, N. Resteghini, M. Robertson, I. Ford, J. Shepherd, C. Packard, B. M. Buckley, J. W. Jukema, A. H. Lichtenstein, E. J. Schaefer, et al. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial J. Lipid Res., January 1, 2010; 51(1): 202 - 209. [Abstract] [Full Text] [PDF]

				T. M. van Himbergen, S. Otokozawa, N. R. Matthan, E. J. Schaefer, A. Buchsbaum, M. Ai, L. J.H. van Tits, J. de Graaf, and A. F.H. Stalenhoef Familial Combined Hyperlipidemia Is Associated With Alterations in the Cholesterol Synthesis Pathway Arterioscler Thromb Vasc Biol, January 1, 2010; 30(1): 113 - 120. [Abstract] [Full Text] [PDF]

				N. R. Matthan, M. Pencina, J. M. LaRocque, P. F. Jacques, R. B. D'Agostino, E. J. Schaefer, and A. H. Lichtenstein Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD J. Lipid Res., September 1, 2009; 50(9): 1927 - 1935. [Abstract] [Full Text] [PDF]

				A. J Tremblay, B. Lamarche, J.-C. Hogue, and P. Couture Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia J. Lipid Res., July 1, 2009; 50(7): 1463 - 1471. [Abstract] [Full Text] [PDF]

				T. M. van Himbergen, N. R. Matthan, N. A. Resteghini, S. Otokozawa, M. Ai, E. A. Stein, P. H. Jones, and E. J. Schaefer Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers J. Lipid Res., April 1, 2009; 50(4): 730 - 739. [Abstract] [Full Text] [PDF]

				S. Nambiar, S. Viswanathan, B. Zachariah, N. Hanumanthappa, and Sridhar Gopalakrishna Magadi Oxidative Stress in Prehypertension: Rationale for Antioxidant Clinical Trials Angiology, April 1, 2009; 60(2): 221 - 234. [Abstract] [PDF]

				S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1672 - 1678. [Abstract] [Full Text] [PDF]

				S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism J. Lipid Res., August 1, 2007; 48(8): 1746 - 1753. [Abstract] [Full Text] [PDF]

				T. Carter High-Dosage Vitamin E Supplementation and All-Cause Mortality Ann Intern Med, July 19, 2005; 143(2): 155 - 155. [Full Text] [PDF]